Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, Merck & Co., Inc. and Prometheus Laboratories Inc.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®


Resources

PER Pulse™ Recap
Three PER Pulse™ Recaps presenting key topics from the 11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®, which was held on March 7, 2015.



PER Pulse™ Recap

PER Pulse™ Recap
Medical Writer: Beth Cameron, PhD



1 of 3
PER Pulse™ Recap

Community Practice Connections: 11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® is a series of short video interviews with leading experts in the treatment of melanoma and other cutaneous malignancies, in which they address a variety of questions commonly faced by practicing oncologists. This first of 3 PER Pulse™ Recaps focuses on novel regional therapy for the treatment of melanoma.

Below are some clinical pearls and interesting facts from the activity:

  • Dr Robert Andtbacka describes several types of regional intralesional treatment options now in clinical trial for melanoma, including intratumoral electroporation of plasmid interleukin 12, PV-10, and talimogene laherparepvec (T-VEC).
  • Dr Andtbacka reports that dermal, subcutaneous, and superficial lymph node lesions were included in the clinical trials for oncolytic immotherapy; separate trials for testing in visceral metastases are ongoing.
  • When oncolytic immunotherapy is used, the optimal outcome is to activate the immune system so that responses in noninjected lesions—including metastases in liver, lung, and/or bone—can also be achieved.

2 of 3
PER Pulse™ Recap

The Community Practice Connections: 11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® is a series of short video interviews with leading experts in the treatment of melanoma and other cutaneous malignancies who address a variety of questions commonly faced by practicing oncologists. This second of 3 PER Pulse™ Recaps focuses on immunotherapy for the treatment of advanced melanoma.

Below are some clinical pearls and interesting facts from the activity:

  • Dr Omid Hamid describes what physicians need to know about PD-1 inhibitors: that response or lack of response to previous immunotherapies does not affect a patient’s chance of responding, and that there are not many adverse events, with most easily treatable once identified. Hypothyroidism and pneumonitis are the most frequent adverse events, and though incidence is relatively low, these need to be top-of-mind when treating patients.
  • According to Dr Hamid, IL-2 is still a standard option for patients with clinically stable metastatic disease, and clinical trials are ongoing with IL-2 as a part of combinatorial therapy with various agents.
  • Dr Hamid adds that while investigations continue to try to determine appropriate biomarkers for immunotherapy, at this time, as long as the patient and disease status is appropriate for one or all types of immunotherapy, he would consider it an option.

3 of 3
PER Pulse™ Recap

The Community Practice Connections: 11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® is a series of short video interviews with leading experts in the treatment of melanoma and other cutaneous malignancies who address a variety of questions commonly faced by practicing oncologists. This third of 3 PER Pulse™ Recaps focuses on combinations of therapy in the treatment of advanced melanoma.

Below are some clinical pearls and interesting facts from the activity:

  • Dr. Ahmad Tarhini describes the rationale behind combination therapy with BRAF inhibitors and MEK inhibitors, including emerging data from 3 phase III trials (COMBI-d, COMBI-v, coBRIM) of the combinations versus BRAF monotherapy. The combinations showed increased response rates, progression- or relapse-free survival, and overall survival, and changed the field so that combination is the standard-of-care for frontline BRAF-mutated metastatic melanoma. Dr. Jeffrey Weber adds that the emerging data of ipilimumab with nivolumab combination immunotherapies is impressive, particularly in patients BRAF-wild-type disease.
  • When asked about combination therapy versus monotherapy for frontline treatment, Dr. Weber explains that for patients with BRAF-wild-type disease and declining performance status, high LDH, M1c disease, or abnormal liver functions, he would consider that patient for the nivolumab and ipilimumab combination expanded-access program. For BRAF-mutated disease, Dr. Weber states that combination targeted therapy is appropriate for patients with a high disease burden and/or aggressive disease.
  • Dr. Weber adds that although the combination of ipilimumab and nivolumab is efficacious, there is a high rate of grade 3/4 adverse events, some prolonged. Sequential therapy with nivolumab and ipilimumab (or vice versa) is being evaluated in clinical trials to determine how they match up with emerging data on concurrent therapy.


Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

Supported by educational grants from Bristol-Myers Squibb, Genentech, Merck & Co., Inc. and Prometheus Laboratories Inc.







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By